Point sur la Recherche & Développement

Lancement de deux nouveaux tests permettant de différencier la COVID-19 des virus hivernaux courants, et des variants de la COVID-19 Paris, France et Camberley, Royaume-Uni – 30 septembre 2021 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, fait un point sur ses activités de R&D. http://novacyt.com/wp-content/uploads/2021/09/Novacyt-Point-sur-la-Recherche-Developpement.pdf

Visit Page

R&D update

Including launch of two new tests to differentiate between COVID-19 and common winter viruses, and between COVID-19 variants Paris, France and Camberley, UK – 30 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&D update. http://novacyt.com/wp-content/uploads/2021/09/Novacyt-RD-update.pdf

Visit Page

Notice of AGM

Paris, France and Camberley, UK – 29 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that following the announcement earlier today the Company’s rescheduled Annual General Meeting (AGM) will be held on Monday, 18 October 2021 at 2pm CEST/1pm BST. http://novacyt.com/wp-content/uploads/2021/09/Notice-of-AGM.pdf

Visit Page